Tag: Anticoagulants
Long-Term Thrombolytic Tx No Benefit in Intermediate-Risk PE
Findings at three years for tenecteplase vs placebo in patients with intermediate-risk pulmonary embolism
Patients Have High Confidence in Self-Testing INR
Seventy-three percent of patients report being confident in adjusting their own warfarin level
ACC: Antithrombotic Benefit Found Lacking in Low-Risk A-Fib
Researchers found low-risk patients fared better without any antithrombotic therapy
Many A-Fib Patients Not Getting Appropriate Anticoagulation Rx
More than 80 percent of ischemic stroke patients weren't getting adequate anticoagulation
NOACs Have Been Widely Adopted Into Practice
Non-vitamin K antagonist oral anticoagulants prescribed more often than vitamin K antagonists
Fewer Major Bleeds With Once- Versus Twice-Daily Enoxaparin
In propensity analysis, patients on enoxaparin once daily had fewer bleeds, fewer deaths at 15, 30 days
Lower Inpatient Costs for Dabigatran, Rivaroxaban in A-Fib
Lower inpatient costs with dabigatran, rivaroxaban versus warfarin for newly diagnosed atrial fibrillation
Many Ischemic Stroke Survivors Not Prescribed Anticoagulants
Reasons for not prescribing OAC include fall risk, poor prognosis, bleeding history, older age, dementia
Continuing Warfarin Protective After Diagnosis of Dementia
Findings in cohort of veterans aged 65 years or older receiving warfarin for nonvalvular atrial fibrillation
PPI Cuts Risk of Warfarin-Related Upper GI Bleeding
Greatest reduction in risk seen for patients also taking antiplatelet drugs or NSAIDs
